Affimed N.V. EBITDA 2011-2026 | AFMD

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Affimed N.V.

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-107 M	-88.1 M	-64 M	-34.7 M	-32.4 M	-19.5 M	-27.3 M	-32 M	-21.3 M	-7.74 M	-15.3 M	-9.99 M	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
-7.74 M	-107 M	-38.3 M

Quarterly EBITDA Affimed N.V.

2024-Q2	2023-Q4	2023-Q3	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-15.6 M	-107 M	-	-29.4 M	-	-	-21.7 M	-	-64 M	-	-17.2 M	-	-34.7 M	-	-11.3 M	-	-32.4 M	-	-9.68 M	-	-19.5 M	-	-9.11 M	-	-27.3 M	-	-	-	-32 M	-	-	-	-21.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-9.11 M	-107 M	-30.1 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	-15.3 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Autolus Therapeutics plc AUTL	-262 M	$ 1.7	3.03 %	$ 452 M	Britain
Happiness Biotech Group Limited HAPP	-6.4 M	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	-180 M	$ 1.61	2.55 %	$ 189 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
BioNTech SE BNTX	-1.4 B	$ 92.14	1.33 %	$ 22.3 B	Germany
AstraZeneca PLC AZN	19.5 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	-101 M	-	-	$ 269 M	USA
CRISPR Therapeutics AG CRSP	-645 M	$ 50.36	0.92 %	$ 4.53 B	Schweiz
BiondVax Pharmaceuticals Ltd. BVXV	-11.9 M	-	0.74 %	$ 768 M	Israel
Compugen Ltd. CGEN	31.8 M	$ 2.8	7.28 %	$ 262 M	Israel
Abcam plc ABCM	-10.1 M	-	-	$ 4.9 B	Britain
Galera Therapeutics GRTX	-2.54 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	-8.64 M	-	-18.52 %	$ 27.3 M	Britain
Enlivex Therapeutics Ltd. ENLV	-14.7 M	$ 0.72	-0.37 %	$ 32.9 M	Israel
Esperion Therapeutics ESPR	60.4 M	$ 3.13	-	$ 651 M	USA
Eton Pharmaceuticals ETON	3.2 M	$ 32.59	-6.89 %	$ 877 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Forte Biosciences FBRX	-70.6 M	$ 21.59	-1.86 %	$ 280 M	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Celyad Oncology SA CYAD	-40.9 M	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	-89 M	-	-7.31 %	$ 87 M	USA
Generation Bio Co. GBIO	-137 M	-	-	$ 344 M	USA
IMV IMV	-10.9 M	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Cyclacel Pharmaceuticals CYCCP	-8.42 M	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	-96.7 M	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	-566 M	-	-	$ 3.37 B	China
Anika Therapeutics ANIK	-5.68 M	$ 14.88	-0.93 %	$ 213 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	-10.7 M	-	5.93 %	$ 314 M	Canada
InflaRx N.V. IFRX	-44.9 M	$ 2.61	5.67 %	$ 176 M	Germany
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 3.4	-1.16 %	$ 5.6 M	Israel
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA